author-photo

Celina D’Cruz

AstraZeneca

34

Papers

1211

Citations

Citation Trend

Filter By

Papers (34) Sort By

JournalConferenceOthers

Abstract 4263: A semi-mechanistic pharmacokinetic-pharmacodynamic (PK-PD) model of savolitinib (AZD6094/HMPL-504), a novel MET inhibitor, to explore extent and duration of target inhibition required for optimal efficacy in the EBC-1 mouse xenograft model

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)
Generation of stable PDX derived cell lines using conditional reprogramming

2017 Molecular Cancer
Show All
- Source
- Cite
- Save
Citations (21)
Abstract P3-04-10: Utility of the orally bioavailable selective estrogen receptor degrader AZD9496 in ESR1 mutant preclinical models of estrogen receptor positive breast cancer

2017 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Abstract 1150: Targeting MET Exon 14 mutations with the selective small molecule inhibitor Savolitinib

2016 Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)
Abstract 3572: AZ5576, a novel potent and selective CDK9 inhibitor, induces rapid cell death and achieves efficacy in multiple preclinical hematological models

2016 Cancer Research
Show All
- Source
- Cite
- Save
Citations (4)
Acquired savolitinib resistance in non-small cell lung cancer arises via multiple mechanisms that converge on MET-independent mTOR and MYC activation

2016 Oncotarget
Show All
- Source
- Cite
- Save
Citations (18)
Abstract 641: Use of conditional reprogramming to develop and characterize cell cultures from patient-derived xenograft (PDX) models of human lung and ovarian cancer

2016 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Response to savolitinib (AZD6094/HMPL-504, a potent and selective MET inhibitor) in a papillary renal cell carcinoma patient harbouring a novel MET activating mutation

2016 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Whole transcriptome profiling of patient-derived xenograft models as a tool to identify both tumor and stromal specific biomarkers.

2016 Oncotarget
Show All
- Source
- Cite
- Save
Citations (22)
AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models.

2016 Cancer Research
Show All
- Source
- Cite
- Save
Citations (121)

© Copyright 2015-2020 Acemap, Inc. Shanghai Jiao Tong University.

沪ICP备18028330号